Methotrexate in psoriatic polyarthritis.

P D Pigatto; E Gibelli; R Ranza; A Rossetti

Home/Archive/PubMed

PubMed · 8073807

Methotrexate in psoriatic polyarthritis.

P D Pigatto·E Gibelli·R Ranza·A Rossetti

View original source ↗Export metadata ↓

Abstract

Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffective, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

Explore related subjects

Arthritis, Psoriatic Female Humans Male Methotrexate Middle Aged Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P D Pigatto, E Gibelli, R Ranza, A Rossetti. 1994. Methotrexate in psoriatic polyarthritis.. https://pubmed.ncbi.nlm.nih.gov/8073807/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Vanishing finger in psoriatic arthritis: a case report.

Dactylitis is a typical phenomenon in psoriatic arthritis, presenting as a "sausage-shaped" finger. Although classically the distal interphalangeal joints are affected, proximal interphalangeal joints and metacarpophalangeal joints are frequently involved. We present a patient who presented with severe psoriatic arthritis of the proximal interphalangeal joint, leading to subtotal disappearance of the phalangeal bones and important shortening of the fourth finger after 10 years of evolution.

Arthritis, Psoriatic↗

PubMed2006

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

OBJECTIVE: To compare the prevalence of cardiovascular diseases and their risk factors between patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and control subjects. METHODS: Data for patients continuously enrolled in an integrated outcomes database between January 1, 2001, and December 31, 2002, with International Classification of Diseases, 9th Revision codes of 714.x (RA), 696.0 (PsA), or 720.0 (AS) were evaluated in this cross-sectional comparative study. Control groups were established for each patient group (1:4 ratio) by matching on the basis of age, sex, geographic region, and length of time in plan. Age- and sex-adjusted prevalence of cardiovascular comorbidities and risk factors were calculated; the prevalence ratio of the comorbidities and risk factors for the patient groups compared with the control population were estimated. Use of selected cardiovascular medications was also compared between patient and control groups. RESULTS: The RA, PsA, and AS cohorts comprised 28,208, 3066, and 1843 patients, respectively. The prevalence ratio of ischemic heart disease (1.5, 1.3, 1.2), atherosclerosis (1.9, 1.4, 1.5), peripheral vascular disease (2.4, 1.6, 1.6), congestive heart failure (2.0, 1.5, 1.8), cerebrovascular disease (1.6, 1.3, 1.7), type II diabetes (1.4, 1.5, 1.2), hyperlipidemia (1.2, 1.2, 1.2), and hypertension (1.3, 1.3, 1.3) were higher in patients than controls. For RA, PsA, and AS, use of angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics, nitrates/vasodilators, anticoagulants, and antihyperlipidemia agents was significantly higher in patients than controls. CONCLUSION: Cardiovascular diseases and their risk factors were more common in patients with RA, PsA, and AS than in matched controls.

Arthritis, Psoriatic↗

PubMed2006

Therapies for psoriatic nail disease. A systematic review.

Nail involvement is common in patients with psoriasis and psoriatic arthritis, affecting 80%-90% of patients at some time. It also has significant effects on quality of life. Psoriatic nail disease can be refractory to treatment, and different features may respond variably to different therapies. The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease.

Arthritis, Psoriatic↗